Sermorelin is the most defensible of the growth-hormone peptides, and it is still not what most clinics selling it imply. The difference between "was once approved for something" and "is approved for this" carries the entire argument.
What it is and how it works
Sermorelin is a synthetic version of the first 29 amino acids of growth-hormone-releasing hormone — the shortest fragment that retains full biological activity. It binds the GHRH receptor on the pituitary and prompts release of the body's own growth hormone.
That mechanism has a real consequence: it depends on a functioning pituitary. Injected growth hormone bypasses the gland entirely and raises levels regardless; sermorelin only amplifies a signal the gland can still answer. It also preserves the natural pulsatile pattern of release and remains subject to feedback from somatostatin, which is the pharmacological argument for preferring it to growth hormone itself.
Its half-life is short — roughly ten to twenty minutes — which is why dosing is daily and usually at night, when the largest natural pulse occurs.
The approval it actually had
Sermorelin was approved as Geref for two purposes: as a diagnostic agent to test pituitary function, and for treating growth hormone deficiency in children with growth failure. Both are paediatric endocrinology, not adult wellness.
It was withdrawn from the US market in 2008. The withdrawal was commercial — the manufacturer discontinued it — rather than the result of a safety finding or an efficacy failure. That distinction is genuinely favourable to sermorelin and is worth stating plainly, because it is the one meaningful difference between it and peptides that never reached approval at all.
What it does not do is transfer to different uses in a different population. A drug approved to treat deficiency in children was never tested to improve body composition in healthy adults.
What clinics sell it for, and what supports that
Anti-ageing and body composition
The reasoning runs: growth hormone declines with age, sermorelin raises growth hormone, therefore sermorelin reverses effects of ageing. The first two steps are true. The third has not been tested. Growth hormone replacement in adults with diagnosed deficiency does modestly change body composition — but those adults have a diagnosed pituitary disorder, and the treatment studied was growth hormone, not sermorelin.
Sleep
Growth hormone release is tied to slow-wave sleep, and some GHRH research in the 1990s suggested effects on sleep architecture. This is the most biologically plausible of the claims and still lacks trials in the population being sold to.
Recovery and injury healing
No human trial supports this for sermorelin. The claim borrows from growth hormone research in catabolic states such as burns and severe illness, which is a different clinical situation entirely.
Compounded is not the same as approved
Because the branded product left the market, sermorelin now reaches patients through compounding pharmacies. Compounding is legal and regulated, and a 503B outsourcing facility operates under real oversight — but what that oversight covers is preparation quality, not whether the drug works for the purpose prescribed.
Practically, this means a compounded sermorelin prescription from a licensed pharmacy is a materially better proposition than a research-chemical vial bought online, and still not equivalent to a drug approved for your indication. The FDA has separately warned about clinics marketing compounded peptides with claims that have not been evaluated.
Safety, monitoring and who should avoid it
Common effects
Injection-site redness and pain are the most frequent. Flushing, headache, dizziness and a metallic taste were reported in the original trials. Most are mild.
What monitoring should look like
IGF-1 is the practical marker of the effect, and a clinic prescribing sermorelin without measuring it before and during treatment is not monitoring anything. Blood glucose is worth watching, since growth hormone reduces insulin sensitivity.
Who should not take it
Anyone with an active malignancy — growth hormone and IGF-1 are growth signals, and this is the clearest contraindication. Anyone with untreated hypothyroidism, since it blunts the response. It is not used in pregnancy. Caution applies with diabetes, given the effect on insulin sensitivity.
Sermorelin, CJC-1295 and growth hormone compared
| Sermorelin | CJC-1295 | Growth hormone (somatropin) | |
|---|---|---|---|
| Regulatory status | Approval withdrawn 2008; compounded | Never approved; FDA Category 2 for compounding | Approved for defined indications |
| Duration of effect | Minutes; daily dosing | Days to a week depending on version | Sustained; daily or weekly products |
| Depends on pituitary | Yes | Yes | No — bypasses it |
| Human outcome data | In children with deficiency | None | Extensive, in deficiency |
Our guide to CJC-1295 covers the peptide most often sold alongside it.
The honest summary
Sermorelin has a documented safety profile, a plausible mechanism, and a history of legitimate approval — three things most marketed peptides lack. What it does not have is any evidence that it delivers the outcomes it is now sold for, in the people it is now sold to. If a clinic is offering it, the questions worth asking are whether IGF-1 will be measured, what result would count as success, and what the plan is if nothing changes.
